Themis Medicare rises on getting DCGI’s nod to import, market Remifentanil 1mg/2mg Powder for Injection

17 Feb 2023 Evaluate

Themis Medicare is currently trading at Rs. 1354.00, up by 10.40 points or 0.77% from its previous closing of Rs. 1343.60 on the BSE.

The scrip opened at Rs. 1359.90 and has touched a high and low of Rs. 1372.75 and Rs. 1337.70 respectively. So far 710 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1434.25 on 16-Dec-2022 and a 52 week low of Rs. 692.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 1372.75 and Rs. 1296.80 respectively. The current market cap of the company is Rs. 1246.06 crore.

The promoters holding in the company stood at 67.18%, while Institutions and Non-Institutions held 0.03% and 32.79% respectively.

Themis Medicare has received approval from Drug Controller General of India (DCGI) for import & marketing of Remifentanil 1mg/2mg Powder for Concentrate for Solution for Injection. The drug been approved for use as an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures, for continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting, and as an analgesic component of monitored anesthesia care in adult patients. Themis will market this drug with the brand name Remithem.

Remifentanil is short-acting narcotic analgesic with a rapid onset & rapid offset of action that offers easy dose titration, predictable and precise intraoperative control, and reduced or rapidly reversed side effects. Due to its distinct pharmacokinetic and pharmacodynamic properties and rapid extra-hepatic clearance, Remifentanil has several applications in general anesthesia and in intensive care where rapid clearance of drug is beneficial. 

Remifentanil was first approved by USFDA in 1996. With the current approval in India, the long wait for the rapid acting narcotic analgesic is over. Remithem will be imported by Themis and marketed in India soon by its well-trained sales team which is currently marketing a range of anesthesia and critical care products to hospitals across the country.

Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.

Themis Medicare Share Price

105.60 -0.70 (-0.66%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×